Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bridion for reversal of rocuronium-induced neuromuscular blockade
NCT03519867Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Aug 2004
- Primary completion
- May 2005
01
Overview
Phase 2, randomised trial of Sugammadex in neuromuscular blockade (NMB), sponsored by Merck & Co. Started Aug 2004; status: completed.
02
Drugs
Sugammadex
03
Conditions
neuromuscular blockade (NMB)
Beyond the preview
Go deeper on NCT03519867.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03519867.